Compare Quantumscape Corp (QS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Recursion Pharmaceuticals Inc — how do they compare? Quantumscape Corp trades at $5.6 (market cap $3.72B), while Recursion Pharmaceuticals Inc trades at $3.01 (market cap $1.63B). The key difference: Quantumscape Corp is far larger — about 2.3× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| QS | RXRX | |
|---|---|---|
Market Cap | $3.72B | $1.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $6.79 |
52-Week Low | $5.86 | $2.84 |
Enterprise Value | $2.89B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $6.05, up 3.24% on the day, amid a bearish technical signal and negative profitability metrics. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, while cash flow remains dependent on financing activities. Recent news highlights a joint research agreement with Honda, providing optimism around solid-state battery development, though earnings misses in recent quarters temper near-term expectations.
The outlook remains speculative with high execution risk as QS transitions from R&D to commercialization. Investor sentiment is cautious, reflected in analyst holds and sells, but partnerships like Honda offer long-term potential. Key risks include sustained losses, EV market demand volatility, and manufacturing scalability challenges against established competitors.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
